ArticleAntimicrobial agents and chemotherapy2014
In vitro combination of voriconazole and miltefosine against clinically relevant molds.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Targeting fungal lipid synthesis for antifungal drug development and potentiation of contemporary antifungals.npj antimicrobials and resistance · 2025Review
- Miltefosine: A Repurposing Drug against Mucorales Pathogens.Journal of fungi (Basel, Switzerland) · 2023Article
- Potential Inhibitory Effect of Miltefosine against Terbinafine-ResistantPathogens (Basel, Switzerland) · 2023Article
- Oral delivery of brain-targeted miltefosine-loaded alginate nanoparticles functionalized with polysorbate 80 for the treatment of cryptococcal meningitis.The Journal of antimicrobial chemotherapy · 2023Article
- In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins ResistantJournal of fungi (Basel, Switzerland) · 2022Article
- Article
- Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.Journal of fungi (Basel, Switzerland) · 2021Review
- Miltefosine AgainstFrontiers in cellular and infection microbiology · 2021Article
- Review
- Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates.Antimicrobial agents and chemotherapy · 2020Article
- Article
- Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis.International journal of nanomedicine · 2019Article
- Review
- Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts.Antimicrobial agents and chemotherapy · 2018Article
- Article
- In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive infections caused by filamentous fungi are a major threat for immunocompromised patients. Innate/acquired resistance to antifungal drugs might necessitate combination therapies. We assessed the potential combination of voriconazole with miltefosine, an original drug with antifungal activity against 33 clinically relevant mold isolates, including both azole-susceptible and -resistant Aspergillus. Using complete inhibition as an endpoint, interactions were indifferent for 32/33 isolates. An alternative 50% inhibition endpoint showed synergistic interactions for 14/33 isolates. Antagonism was absent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.